Cel Sci (CVM) Non-Current Deffered Revenue (2010 - 2016)
Cel Sci (CVM) posted Non-Current Deffered Revenue of $17609.0 for Q3 2016, down 4.18% sequentially from $18378.0 in Q2 2016, and up 95.09% YoY from $9026.0 in Q4 2015.
Cel Sci (CVM) Non-Current Deffered Revenue (2010 - 2016) Analysis & Trends
Cel Sci has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $17609.0 in Q3 2016.
- Quarterly Non-Current Deffered Revenue rose 95.09% year-over-year to $17609.0 in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $17609.0 (up 95.09% YoY) and the FY2016 annual result came in at $17609.0, up 95.09% from the prior year.
- Non-Current Deffered Revenue slipped to $17609.0 in Q3 2016 per CVM's latest filing, from $18378.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $18378.0 in Q2 2016 and troughed at $646.0 in Q2 2012.
- A 4-year average of $8819.7 and a median of $9026.0 in 2015 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2012 and 2013: Non-Current Deffered Revenue tumbled 89.3% in 2012, then jumped 472.55% in 2013.
- Over 4 years, Non-Current Deffered Revenue stood at $4195.0 in 2012, then surged by 141.17% to $10117.0 in 2013, then slipped by 10.78% to $9026.0 in 2015, then soared by 95.09% to $17609.0 in 2016.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $17609.0, $18378.0, and $9026.0 for Q3 2016, Q2 2016, and Q3 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 17,609.00 |
| Jun 30, 2016 | 18,378.00 |
| Sep 30, 2015 | 9,026.00 |
| Mar 31, 2013 | 10,117.00 |
| Sep 30, 2012 | 4,195.00 |
| Jun 30, 2012 | 646.00 |
| Mar 31, 2012 | 1,767.00 |
| Dec 31, 2011 | -1,509.00 |
| Sep 30, 2011 | -3,699.00 |
| Jun 30, 2011 | 6,035.00 |
| Sep 30, 2010 | -6,080.00 |